Evidence map›Paper›PMID 30569431›Full record

ArticleNeuroscience bulletin2019

NMDA Receptor Antagonist MK801 Protects Against 1-Bromopropane-Induced Cognitive Dysfunction.

Lin Xu, Xiaofei Qiu, Shuo Wang, Qingshan Wang, Xiu-Lan Zhao

Open access · bronzeAbstract read
In one paragraph

Article in Neuroscience bulletin, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 21 citations in OpenAlex.

  1. Current issues in molecular biology · 2025
    Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Lin XuSchool of Public Health, Shandong University, Jinan, 250012, China.
Xiaofei QiuSchool of Public Health, Shandong University, Jinan, 250012, China.
Shuo WangSchool of Pharmacy, Liaocheng University, Liaocheng, 252000, China.
Qingshan WangSchool of Public Health, Dalian Medical University, Dalian, 116044, China. wangq4@126.com.
Xiu-Lan ZhaoSchool of Public Health, Shandong University, Jinan, 250012, China. zhao.xl@sdu.edu.cn.
Shandong University · CNDalian Medical University · CNLiaocheng University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Occupational exposure to 1-bromopropane (1-BP) induces learning and memory deficits. However, no therapeutic strategies are currently available. Accumulating evidence has suggested that N-methyl-D-aspartate receptors (NMDARs) and neuroinflammation are involved in the cognitive impairments in neurodegenerative diseases. In this study we aimed to investigate whether the noncompetitive NMDAR antagonist MK801 protects against 1-BP-induced cognitive dysfunction. Male Wistar rats were administered with MK801 (0.1 mg/kg) prior to 1-BP intoxication (800 mg/kg). Their cognitive performance was evaluated by the Morris water maze test. The brains of rats were dissected for biochemical, neuropathological, and immunological analyses. We found that the spatial learning and memory were significantly impaired in the 1-BP group, and this was associated with neurodegeneration in both the hippocampus (especially CA1 and CA3) and cortex. Besides, the protein levels of phosphorylated NMDARs were increased after 1-BP exposure. MK801 ameliorated the 1-BP-induced cognitive impairments and degeneration of neurons in the hippocampus and cortex. Mechanistically, MK801 abrogated the 1-BP-induced disruption of excitatory and inhibitory amino-acid balance and NMDAR abnormalities. Subsequently, MK801 inhibited the microglial activation and release of pro-inflammatory cytokines in 1-BP-treated rats. Our findings, for the first time, revealed that MK801 protected against 1-BP-induced cognitive dysfunction by ameliorating NMDAR function and blocking microglial activation, which might provide a potential target for the treatment of 1-BP poisoning.

Indexed as

AnimalsBrainCognitive DysfunctionDisease Models, AnimalDizocilpine MaleateExcitatory Amino Acid AntagonistsHydrocarbons, BrominatedInflammasomesMaleMaze LearningMicrogliaNeuronsNLR Family, Pyrin Domain-Containing 3 ProteinNootropic AgentsRandom AllocationRats, Wistar1-bromopropaneDizocilpine MaleateExcitatory Amino Acid AntagonistsHydrocarbons, BrominatedInflammasomesNLR Family, Pyrin Domain-Containing 3 ProteinNlrp3 protein, ratNootropic AgentsReceptors, N-Methyl-D-Aspartate1-BromopropaneCognitive dysfunctionMicrogliaMK801NLRP3 inflammasomeN-methyl-D-aspartate receptors

Identifiers

PMID30569431
PMCPMC6426915
OpenAlexW2904494197

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.